Company
Headquarters: New Taipei City, Taiwan
CEO: Dr. Mei-Chun Yang
TW$3.06 Billion
TWD as of Jan. 1, 2024
US$99.6 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycosphingolipid antigen production and identification; monoclonal antibody production; cancer drug screening; stable cell line production for monoclonal antibody; and pharmacology/pharmacokinetics assessment. The company offers GNX102, a humanized antibody for cancer-specific glycan prevalent on several types of cancer cells, such as gastric, colon, and pancreatic cancer, as well as develops bi-specific antibody generate armed T-cells targeting glycan antigens on cancer cells. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
GlycoNex InCorp has the following listings and related stock indices.
Stock: TWSE: 4168 wb_incandescent